Bacterial Endotoxins Test: Methods and Workflow
Contents
- What the BET measures
- Main method families
- Current chapter references and an upcoming change
- A practical BET workflow
- Example result-review worksheet
- Common mistakes to avoid
- Fictional example
- Frequently asked questions
- Does a negative sterility test mean endotoxin is absent?
- Can a lab replace LAL with a recombinant method?
- What makes a BET result invalid?
- Is the IPC endotoxin guide an official IP requirement?
- Related reading
- References
In short: The bacterial endotoxins test (BET) detects or measures endotoxins, a pyrogenic contaminant associated with Gram-negative bacteria. QC teams use it where the product’s applicable standard requires control of endotoxin risk. Choose and run the method from the current pharmacopoeia, product specification and approved procedure, and show that the method works with the specific product matrix.
What the BET measures
Bacterial endotoxins are components of the outer membrane of Gram-negative bacteria. They are not the same as viable bacteria: endotoxin activity can remain even after bacterial cells have died, so a sterility result alone does not answer the endotoxin question. The Indian Pharmacopoeia Commission’s Guidelines on the Bacterial Endotoxins Tests, Version 2.0 (published in January 2023 as a proposed general chapter for public comment), explains this distinction and describes common sources such as water, raw materials, excipients, packaging components and inadequately controlled equipment.
For products represented as sterile and/or pyrogen-free in the United States, 21 CFR 211.167(a) requires appropriate laboratory testing for each batch and written procedures that are followed. The applicable product monograph, market authorisation, pharmacopoeia and approved specification determine the actual test and acceptance limit. Do not take a limit from a generic article or transfer it from another product.
Main method families
The method names below describe broad principles. They do not reproduce compendial procedures or acceptance criteria. USP <85> describes the traditional BET using horseshoe-crab amoebocyte lysate. USP <86> describes additional approaches that use recombinant reagents. The IPC 2023 text was a proposal published for public comment and is labelled as information, not an official requirement; use the live applicable chapter for all controlled testing.
| Method family | What the instrument or analyst observes | General output |
|---|---|---|
| Gel-clot | Whether a firm clot forms under the specified test conditions | A limit test or a semi-quantitative endpoint, according to the method used |
| Kinetic turbidimetric | The change in turbidity over time as the reaction develops | A quantitative result interpreted against the method’s standard curve |
| Chromogenic | Colour development, measured at an endpoint or followed over time | A quantitative result interpreted against the method’s standard curve |
| Recombinant reagent methods | A response from recombinant Factor C (rFC) or recombinant cascade reagent (rCR) | A non-animal-derived alternative approach; applicability depends on the governing compendium and product requirements |
The first three method families are described in the IPC 2023 proposal as gel-clot, kinetic turbidimetric and chromogenic approaches. The guide groups chromogenic procedures into kinetic and endpoint formats. USP’s official summary says <85> uses horseshoe-crab lysate and <86> includes rFC and rCR techniques. A method that is available in a pharmacopoeia is not automatically permitted for every product or market: check the chapter’s status, monograph, registration commitments and quality-unit approval.
Current chapter references and an upcoming change
In the official USP preview checked for this guide, General Chapter <85>, Bacterial Endotoxins Test, is listed as USP–NF 2017. USP General Chapter <86>, Bacterial Endotoxins Test Using Recombinant Reagents, is listed as 2024. Its preview says that <86> is not currently an “applicable” chapter under the USP General Notices; unless an individual monograph specifies it, those tests are alternative methods and must meet the applicable requirements for alternative methods.
EDQM states that chapter 2.6.14, Bacterial endotoxins, is revised in European Pharmacopoeia Issue 13.1 (2026) and that the revision adds a fluorimetric endpoint method using rFC as method G and that the revised text is to come into force on 1 January 2027. This is a future implementation date as of 10 November 2026. Do not treat the revised method as already in force; check the live Ph. Eur. status and your applicable implementation plan.
IPC’s introduction pages for IP 2026 list General Chapter 2.2.3, Bacterial Endotoxins, among the general chapters upgraded in that edition. IPC’s separate Version 2.0 text was published for public comment as a general chapter proposed for IP Addendum 2024; it should not be used to infer that every method detail remains unchanged in IP 2026. Use the official controlled IP 2026 text and its amendments for Indian work.
A practical BET workflow
- Confirm whether the test applies. Check the product’s current specification, monograph, registration commitments and market requirements. Confirm whether the test is a release requirement, in-process check or another defined control.
- Choose the authorised method. Identify the governing chapter and its current version. Confirm whether the selected technique is an applicable compendial method or an alternative requiring additional justification, validation or regulatory acceptance. A change from one assay format to another needs formal assessment and change control.
- Define the product-specific limit from the right source. Use the applicable product monograph or approved specification and the governing chapter. Limits depend on product and intended use; this guide gives no universal numeric value or calculation shortcut.
- Demonstrate method suitability for the product matrix. Product composition can inhibit or enhance the assay response. Run the product-specific suitability work required by the applicable method, including the positive product control or equivalent controls. Establish that the selected sample preparation and dilution allow reliable detection without exceeding the method’s permitted dilution.
- Prepare standards, controls, reagents and sample. Follow the current procedure and reagent manufacturer’s instructions for storage, reconstitution, mixing, equipment and timing. Use only qualified endotoxin standards and suitable consumables. Record lot identifiers and preparation details so a reviewer can trace each input.
- Run the test with all required controls. Include the negative control and method-specific positive, sensitivity or standard-curve controls required by the current chapter. Apply the control criteria exactly as written. Do not substitute an in-house threshold for a compendial criterion without documented scientific justification and required approval.
- Review validity before comparing the sample result. First confirm that controls and system suitability are acceptable. If a control fails, treat the run as potentially invalid and investigate it under the approved procedure; a failed control does not automatically establish that the product is out of specification.
- Calculate, compare and report. Use the method’s approved calculation and units, verify any dilution factor, and compare the valid result with the product-specific specification. Preserve raw instrument output and calculation checks. Have the result reviewed according to the laboratory’s approved responsibilities.
- Investigate atypical or failing results. Follow the laboratory’s OOS, invalid-assay and deviation procedures. Consider sample preparation, reagent and standard lots, analyst technique, equipment, product interference and manufacturing or formulation changes. Do not repeat tests only to obtain a passing result or discard an initial valid result without a documented, scientifically sound basis.
Example result-review worksheet
This blank table can help a reviewer confirm that the necessary information is present. The fields are a practical example, not a pharmacopoeial template or acceptance specification.
| Review item | Record or reference |
|---|---|
| Product, batch and specification version | |
| Governing pharmacopoeia and chapter version | |
| BET method and approved procedure number | |
| Product-specific endotoxin limit and source | |
| Suitability status and sample preparation | |
| Reagent, standard and consumable lot identifiers | |
| Required controls and their results | |
| Raw result, units and calculation check | |
| Validity decision and result disposition | |
| Analyst, reviewer and investigation reference |
For product-batch documentation, retain records at least one year after expiry of the respective product batch. EU GMP Volume 4 Chapter 4 §4.11 specifies the longer of one year after expiry or five years after Qualified Person certification for batch documentation; 21 CFR 211.180(a) sets at least one year after expiry for applicable US drug-product records. Follow any longer applicable retention requirement.
Common mistakes to avoid
- Confusing endotoxin with sterility: A sample can have no recoverable viable bacteria and still contain endotoxin. These tests answer different questions.
- Using a generic limit: Find the value in the approved product-specific source and confirm its units and basis before analysis.
- Skipping product suitability: Reagent controls alone do not show that a particular formulation has no interfering effect.
- Assuming every chapter is immediately applicable: USP <86> and the upcoming Ph. Eur. 2.6.14 changes have specific status and dates. Confirm the version in force for the intended market.
- Ignoring control failures: A failed control may invalidate the run. Record and investigate it before interpreting the product result.
- Using a remembered procedure after a change: Reagent, instrument, formulation, sample-preparation or method changes can affect suitability. Assess the change against the current text and approved change-control procedure.
- Treating local choices as compendial limits: Example in-house criterion: a laboratory may require a second-person review of calculations before reporting; that is a site control, not a pharmacopoeial requirement.
Fictional example
A QC analyst tests a sterile liquid product with a quantitative BET. The instrument reports a result within the product limit, but the positive product control does not meet the method’s suitability criterion. The analyst does not release the assay as passing. The run is documented as invalid under the procedure, and the team checks sample dilution, reagent preparation and possible product interference. After an approved investigation establishes a suitable preparation, the laboratory repeats the test under the authorised method and records both the original invalid run and the valid result.
Frequently asked questions
Does a negative sterility test mean endotoxin is absent?
No. Sterility testing looks for viable microorganisms under its specified conditions. Endotoxin can remain after Gram-negative bacteria have died, so endotoxin control requires its own applicable test.
Can a lab replace LAL with a recombinant method?
Check the applicable monograph, compendium, product authorisation and market requirements first. USP <86> (2024) describes recombinant reagents but identifies the chapter as an alternative unless specified in an individual monograph. Ph. Eur. 2.6.14’s revised method G is scheduled for implementation from 1 January 2027.
What makes a BET result invalid?
The relevant chapter’s controls or system-suitability criteria may not be met, or a documented execution problem may affect the result. Follow the method and approved invalid-assay procedure; do not decide validity from the sample result alone.
Is the IPC endotoxin guide an official IP requirement?
No. IPC published its Guidelines on the Bacterial Endotoxins Tests, Version 2.0 (2023), as a proposal for public comment, and the text is labelled as information, not an official requirement. Use the controlled current IP chapter for official Indian compendial requirements.
Related reading
- Sterility testing in pharmaceutical products
- Antimicrobial effectiveness testing
- Pharma microbiology interview questions
- SOP for microbial culture management
References
- Electronic Code of Federal Regulations, 21 CFR 211.167(a), Special testing requirements, current text checked 5 November 2026: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/section-211.167
- Electronic Code of Federal Regulations, 21 CFR 211.180(a), General requirements, current text checked 6 November 2026: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/section-211.180
- United States Pharmacopeia, USP–NF General Chapter <85>, Bacterial Endotoxins Test (2017 chapter text): https://doi.org/10.31003/USPNF_M98830_02_01
- United States Pharmacopeia, USP–NF General Chapter <86>, Bacterial Endotoxins Test Using Recombinant Reagents (2024): https://doi.org/10.31003/USPNF_M16015_02_01
- United States Pharmacopeia, USP Endotoxin Reference Standard, summary of USP General Chapters <85> and <86>: https://pages.usp.org/endotoxin-rs
- European Directorate for the Quality of Medicines & HealthCare, European Pharmacopoeia: New Content, Issue 13.1 (2026), revised chapter 2.6.14 and implementation date: https://www.edqm.eu/documents/52006/278487/Content_13.1_90010E.pdf/53753e66-d285-6e48-2fcc-dcf18f17cd95
- European Directorate for the Quality of Medicines & HealthCare, FAQ on revised Ph. Eur. 2.6.14 and recombinant Factor C method G (Issue 13.1, implementation 1 January 2027): https://faq.edqm.eu/pages/viewpage.action?pageId=143130675
- Indian Pharmacopoeia Commission, Introduction Pages IP 2026, tenth edition, listing General Chapter 2.2.3, Bacterial Endotoxins: https://www.ipc.gov.in/images/ARnD/Introduction-Pages-IP-2026.pdf
- Indian Pharmacopoeia Commission, Guidelines on the Bacterial Endotoxins Tests, Version 2.0 (proposal for public comment, 20 January 2023; labelled as information, not an official requirement): https://www.ipc.gov.in/images/Guidelines_on_Bacterial_Endotoxins_Tests_Version_2.0_20.01.2023.pdf
- European Commission, EudraLex Volume 4, Chapter 4: Documentation (revision 1, effective 30 June 2011): https://health.ec.europa.eu/document/download/104b3eb8-81a7-4858-9419-cb06562adb66_en?filename=chapter4_01-2011_en.pdf
Related articles
CCS Gap Assessment Checklist for Pharma Sterile Sites
Use this EU GMP Annex 1 based CCS gap assessment checklist to map contamination controls, record evidence, assess gaps and plan actions for a sterile site.
Growth Promotion Test of Culture Media: A Practical Guide
Learn how to qualify culture media through growth promotion testing, assess results, document each lot and investigate failures using compendial methods.
Pharma Microbiology Interview Questions for Freshers
Pharma microbiology interview questions for freshers with model answers on sterility testing, media, MLT, endotoxin, environmental monitoring and aseptic practice.
SOP on Maintenance and Preparation of Anaerobic Culture Suspension
Example SOP for maintaining Clostridium sporogenes and preparing an anaerobic culture suspension that delivers 10 to 100 CFU per inoculum for microbial limit testing.